Thrombodynamics parameters in individuals vaccinated against SARS-CoV-2

Drapkina, О. М.; Бернс, С. А.; Gorshkov, A. Yu.; Yavelov, I. S.; Shishkova, V. N.; Ryzhakova, L. N.; Иванова, А. А.; Veretennikova, A. V.; Karateev, R. A.; Arablinsky, N. A.

doi:10.17116/profmed20212412124

Cited by 6 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data obtained by Russian scientists [ 44 ] made it possible to assert that indicators of plasma hemostasis, such as the stationary and initial thrombus growth rate, growth retardation, density and size of the clot, and the time of appearance of spontaneous thrombi, do not undergo statistically significant changes within 42 days following the introduction of the first component of vaccines Sputnik V and CoviVac. Since these indicators reflect the state of plasma hemostasis, it can be concluded that, during the observation period, no laboratory signs of significant changes in hemostasis were found in those vaccinated with the Sputnik V and CoviVac vaccines, compared with the indicators at the initial observation point.…”

Section: Discussionmentioning

confidence: 99%

Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern

Svetlova

Gustin

Manuvera

et al. 2022

IJMS

View full text Add to dashboard Cite

Mutations in surface proteins enable emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to escape a substantial fraction of neutralizing antibodies and may thus weaken vaccine-driven immunity. To compare available vaccines and justify revaccination, rapid evaluation of antibody (Ab) responses to currently circulating SARS-CoV-2 variants of interest (VOI) and concern (VOC) is needed. Here, we developed a multiplex protein microarray-based system for rapid profiling of anti-SARS-CoV-2 Ab levels in human sera. The microarray system was validated using sera samples from SARS-CoV-2-free donors and those diagnosed with COVID-19 based on PCR and enzyme immunoassays. Microarray-based profiling of vaccinated donors revealed a substantial difference in anti-VOC Ab levels elicited by the replication-deficient adenovirus vector-base (Sputnik V) and whole-virion (CoviVac Russia COVID-19) vaccines. Whole-virion vaccine-induced Abs showed minor but statistically significant cross-reactivity with the human blood coagulation factor 1 (fibrinogen) and thrombin. However, their effects on blood clotting were negligible, according to thrombin time tests, providing evidence against the concept of pronounced cross-reactivity-related side effects of the vaccine. Importantly, all samples were collected in the pre-Omicron period but showed noticeable responses to the receptor-binding domain (RBD) of the Omicron spike protein. Thus, using the new express Ab-profiling system, we confirmed the inter-variant cross-reactivity of the anti-SARS-CoV-2 Abs and demonstrated the relative potency of the vaccines against new VOCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern

Svetlova

Gustin

Manuvera

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…В РФ зарегистрированы несколько типов вакцин, различающиеся по механизму действия: векторные (Гам-КОВИД-Вак, Гам-КОВИД-Вак-Лио, Гам-КОВИД-Вак-М, Спутник Лайт), вакцины на основе пептидных антигенов (ЭпиВакКорона и ЭпиВакКорона-Н), а также инактивированная цельновирионная вакцина Ко-виВак 2 . В государственном реестре РФ 18 марта 2022г зарегистрирована субъединичная рекомбинантная вакцина Конвасэл 3 . Данные литературы свидетельствуют о том, что уровень специфических антител (АТ) IgG к S белку коронавируса SARS-CoV-2 в плазме крови напрямую влияет на эффективность поствакцинального иммунитета.…”

Section: Key Messages What Is Already Known About the Subject?unclassified

“…Было продемонстрировано, что вакцинация КовиВак и Гам-КОВИД-Вак не оказывает статистически значимого влияния на состояние плазменного гемостаза, более того, за вре-мя наблюдения не было зарегистрировано ни одного случая артериального или венозного тромбоза и ни одного случая развития серьезных нежелательных явлений. При этом вакцины Гам-КОВИД-Вак и КовиВак продемонстрировали удовлетворительную иммуногенность, более выраженную в группе вакцинированных Гам-КОВИД-Вак [3].…”

Section: Key Messages What Is Already Known About the Subject?unclassified

“…Однако в представленном выше исследовании [3] не оценивалось наличие корреляционной связи между приростом титра АТ и изменениями в показателях плазменного гемостаза после проведенной вакцинации от COVID-19. Настоящее исследование, проведенное в рамках более детального определения эффективности и безопасности использования отечественных вакцин, позволяет в определенной мере ответить на данный вопрос.…”

Section: Key Messages What Is Already Known About the Subject?unclassified

“…№ 30-4/И/2-9825. Временные методические рекомендации: "Порядок проведения вакцинации взрослого населения против COVID-19" 3. Государственный реестр лекарственных средств.…”

unclassified

See 2 more Smart Citations

Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac

Drapkina¹,

Бернс²,

Gorshkov³

et al. 2022

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines.Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people — CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test.Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies.Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis.

show abstract

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Berns,

Veremeyev,

Savicheva

et al. 2024

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic was not only a serious challenge for the healthcare system around the world, but also an incentive for intensive research and development for the introduction of innovative technologies and drugs, in particular vaccines against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). The first vaccination campaigns provided significant protection against severe disease course and hospitalization. However, new SARS-COV-2 variants require further comprehensive research and the introduction of booster vaccination. Booster vaccination is the most important tool for immunostimulation and increase of protection duration against the severe disease course. The study of booster vaccines, including BioNTech/Pfizer, Moderna, Oxford AstraZeneca, Sputnik V, Sinopharm и Covaxin vaccines, sheds light on their unique action mechanisms and contribution to long-term immunity. The analysis of clinical data demonstrates their effectiveness and safety. The review summarizes modern knowledge about booster vaccinations against the COVID-19 with focus on action mechanisms and efficiency. In addition, the immune system function in response to COVID-19 is considered, while the role of memory cells, antibody and cellular immunity reactions are emphasized.

show abstract

Thrombodynamics parameters in individuals vaccinated against SARS-CoV-2

Cited by 6 publications

References 11 publications

Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern

Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern

Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Contact Info

Product

Resources

About